About: Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (nl) Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant (en)
skos:prefLabel	Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (nl) Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant (en)
name	Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (nl) Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant (en)
title	wds:Q65347361-2087286B-B4DB-4F3B-A83C-829D31ED5E08
title	A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor (en)
end time	wds:Q65347361-B26C3A44-99AE-4366-AB8F-09D7862FCDD5
end time	2016-12-13 00:00:00Z (xsd:dateTime)
instance of	wds:Q65347361-D2084BCA-D2C4-4432-9A79-4662F0D0A9C4
instance of	clinical trial
start time	wds:Q65347361-FF60E4D1-58DE-4E73-BC9E-F0E87977BD31
start time	2015-03-13 00:00:00Z (xsd:dateTime)
country	wds:Q65347361-09D99CD8-2808-4504-AFDB-EE9BBF8E0AFE wds:Q65347361-50567248-F863-42D9-80AD-8708F2DEB476 wds:Q65347361-72FE0A80-1D4A-4C12-A720-0ACE38BB1A7F wds:Q65347361-7D63348F-F74B-4A0D-892B-6C0AE9EDD303 wds:Q65347361-9BE08F91-BC2C-49C2-9663-570C87EB46DD wds:Q65347361-C5534303-5886-4724-B2BC-A556D881E191
country	Italy Spain France Belgica metro station United States of America Germany
research site	wds:Q65347361-054B8B05-1A9A-4A04-A3EC-186463E2F881 wds:Q65347361-0C6202D8-44A8-4E69-81C3-F2FD7DAF363F wds:Q65347361-5C27387F-7FAC-4656-B2A2-CEFB5FD51FBB wds:Q65347361-663CD30A-AF49-4EF1-95E8-F779D8A2A8FE wds:Q65347361-B78972DD-C24E-4B67-9A73-E9F1E38C365D wds:Q65347361-E6C25876-BF1B-43CD-A853-EEAC3B4B5305
research site	AZ Groeninge Hospital Universitario Ramón y Cajal Hospital Universitario Virgen del Rocío Henry Ford Health System Hospital del Mar Policlinico Umberto I
minimum age	wds:Q65347361-9250FB97-F364-4B13-B713-B066F84E578B
minimum age	18 (xsd:decimal)
number of participants	wds:Q65347361-583F4927-BB4C-4202-B2CD-3D692387048C
number of participants	97 (xsd:decimal)
study type	wds:Q65347361-78D5C9A2-EC6C-45A4-98D4-7563FB92FCA7
study type	interventional study
ClinicalTrials.gov ID	wds:Q65347361-B6D32338-8B89-4FEA-B83E-F51C51340D46
ClinicalTrials.gov ID	NCT02374099
clinical trial phase	wds:Q65347361-01EABB38-075F-4020-8968-E7B13F1C45FF
clinical trial phase	phase II clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q65347361

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software